Jump to main content
Jump to site search

Issue 7, 2020
Previous Article Next Article

CuS@PDA–FA nanocomposites: a dual stimuli-responsive DOX delivery vehicle with ultrahigh loading level for synergistic photothermal–chemotherapies on breast cancer

Author affiliations

Abstract

In this study, CuS@PDA nanoparticles were synthesized and used to create a novel tumor-targeting nanocomposite platform composed of copper sulfide@polydopamine–folic acid/doxorubicin (CuS@PDA–FA/DOX) for performing both photothermal and chemotherapeutic cancer treatment. The nanocomposite platform has ultrahigh loading levels (4.2 ± 0.2 mg mg−1) and a greater photothermal conversion efficiency (η = 42.7%) than CuS/PDA alone. The uptake of CuS@PDA–FA/DOX nanocomposites is much higher in MCF-7 cells than in A549 cells because MCF-7 cells have much higher folic acid receptors than A549. Under near infrared (NIR) irradiation, the CuS@PDA–FA/DOX system using a synergistic combination of photothermal therapy and chemotherapy yields a better therapeutic effect than either photothermal therapy or chemotherapy alone. The treatment is very effective with the cell viability is only 5.6 ± 1.4%.

Graphical abstract: CuS@PDA–FA nanocomposites: a dual stimuli-responsive DOX delivery vehicle with ultrahigh loading level for synergistic photothermal–chemotherapies on breast cancer

Back to tab navigation

Supplementary files

Article information


Submitted
01 Nov 2019
Accepted
13 Jan 2020
First published
14 Jan 2020

J. Mater. Chem. B, 2020,8, 1396-1404
Article type
Paper

CuS@PDA–FA nanocomposites: a dual stimuli-responsive DOX delivery vehicle with ultrahigh loading level for synergistic photothermal–chemotherapies on breast cancer

S. Zhang, X. Liu, Q. Sun, O. Johnson, T. Yang, M. Chen, J. Wang and W. Chen, J. Mater. Chem. B, 2020, 8, 1396
DOI: 10.1039/C9TB02440A

Social activity

Search articles by author

Spotlight

Advertisements